Literature DB >> 17568997

No association of MDM2 SNP309 with risk of glioblastoma and prognosis.

Soufiane El Hallani1, Yannick Marie, Ahmed Idbaih, Mathieu Rodero, Blandine Boisselier, Florence Laigle-Donadey, François Ducray, Jean-Yves Delattre, Marc Sanson.   

Abstract

The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17568997     DOI： 10.1007/s11060-007-9416-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  24 in total

1.  Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population.

Authors:  Zhibin Hu; Hongxia Ma; Daru Lu; Ji Qian; Jiannong Zhou; Yijiang Chen; Lin Xu; Xinru Wang; Qingyi Wei; Hongbing Shen
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

2.  MDM2 SNP309 and SNP354 are not associated with lung cancer risk.

Authors:  Sharon R Pine; Leah E Mechanic; Elise D Bowman; Judith A Welsh; Stephen C Chanock; Peter G Shields; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

3.  Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.

Authors:  Aslihan Petenkaya; Betul Bozkurt; Ozlem Akilli-Ozturk; Hatice Seda Kaya; Bala Gur-Dedeoglu; Isik G Yulug
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

4.  Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.

Authors:  Hongxia Ma; Zhibin Hu; Xiangjun Zhai; Shui Wang; Xuechen Wang; Jianwei Qin; Guangfu Jin; Jiyong Liu; Xinru Wang; Qingyi Wei; Hongbing Shen
Journal:  Cancer Lett       Date:  2005-11-08       Impact factor: 8.679

5.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Authors:  Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

6.  MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.

Authors:  Marijke Wasielewski; Jord H A Nagel; Cecile Brekelmans; Jan G M Klijn; Ans van den Ouweland; Hanne Meijers-Heijboer; Mieke Schutte
Journal:  Breast Cancer Res Treat       Date:  2006-11-02       Impact factor: 4.872

7.  Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Authors:  Christine S Walsh; Carl W Miller; Beth Y Karlan; H Phillip Koeffler
Journal:  Gynecol Oncol       Date:  2006-11-21       Impact factor: 5.482

8.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.

Authors:  Yuan Hong; Xiaoping Miao; Xuemei Zhang; Fang Ding; Aiping Luo; Yongli Guo; Wen Tan; Zhihua Liu; Dongxin Lin
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

Review 9.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

10.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.

Authors:  Helge Lind; Shanbeh Zienolddiny; Per Olav Ekstrøm; Vidar Skaug; Aage Haugen
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396
View more
  5 in total

1.  MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.

Authors:  Yan Wan; Wei Wu; Zhihua Yin; Peng Guan; Baosen Zhou
Journal:  BMC Cancer       Date:  2011-05-29       Impact factor: 4.430

2.  Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma.

Authors:  Simona Ognjanovic; Ghyslaine Martel; Carlos Manivel; Magali Olivier; Erica Langer; Pierre Hainaut
Journal:  Sarcoma       Date:  2012-03-07

Review 3.  Recent advances in the molecular understanding of glioblastoma.

Authors:  Fonnet E Bleeker; Remco J Molenaar; Sieger Leenstra
Journal:  J Neurooncol       Date:  2012-01-20       Impact factor: 4.130

4.  SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.

Authors:  Kanako Okamoto; Ryosuke Tsunematsu; Tomoko Tahira; Kenzo Sonoda; Kazuo Asanoma; Hiroshi Yagi; Tomoko Yoneda; Kenshi Hayashi; Norio Wake; Kiyoko Kato
Journal:  BMC Med Genet       Date:  2015-08-21       Impact factor: 2.103

5.  p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.

Authors:  M Dimitriadi; G Poulogiannis; L Liu; L M Bäcklund; D M Pearson; K Ichimura; V P Collins
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.